Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effects of flexibly dosed Brexpiprazole
monotherapy in the improvement of early-episode schizophrenia through the assessment of
social functioning, efficacy, and tolerability. Early-episode schizophrenia is defined as
episodes occurring ≤ 5 years after the onset of the first episode.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.